All about 2024 Saxenda lawsuit: Saxenda belongs to a class of medications called DPP-4 inhibitors. Exenatide and liraglutide belong to a class of medications referred to as GLP-1 receptor agonists. These two classes of medication, DPP-4 inhibitors, and GLP-1 receptor agonists are called incretin-based therapies because incretin hormones lower blood sugar by stimulating or sustaining the production of insulin. What all incretin drugs have in common is that they manipulate GLP-1 hormone levels in the body. The underlying problem with incretin drugs is that they are known to cause abnormal cell growth in the pancreas. Since incretin drugs first came on the market there has been concern that the effect of these drugs on the pancreas may cause pancreatic cancer. But, as we discuss below, this link has not been scientifically established, at least not yet. Read more information at Saxenda lawsuit.
Saxenda (liraglutide) is a brand-name prescription drug approved by the U.S. Food & Drug Administration (FDA) for weight loss and long-term weight management. It belongs to a class of medications known as glucagon-like peptide 1 (GLP-1) receptor agonists, which work by mimicking gut peptides and helping to regulate blood sugar levels. While Saxenda has been touted as a promising solution for individuals struggling with obesity, the drug has also been associated with a range of concerning Saxenda side effects.
In addition, Dr. Andrew Boxer, a gastroenterologist at Gastroenterology Associates of New Jersey, is among a number of gastroenterologists who said he is seeing an increased number of patients coming into his practice complaining of side effects from these types of drugs. In an article in Healthline, Dr. Boxer continued stating that “I was seeing a tremendous amount of people coming in just with nausea, vomiting, and feelings of fullness, early satiety, just not feeling well … Universally these patients were on GLP-1’s.” (emphasis added). Moreover, doctors have stated additional similar cases are coming to light as the popularity of these drugs has soared.
A resident of Kentucky has initiated a lawsuit against Novo Nordisk A/S and its subsidiaries, accusing the company of failing to warn about the potential risk of permanent stomach paralysis caused by its weight loss medication, Saxenda (liraglutide). The plaintiff consumed Saxenda from March 2019 to April 2021 and is now experiencing gastroparesis, which has resulted in severe consequences such as persistent vomiting and abdominal pain, requiring multiple visits to the hospital. The lawsuit alleges that since the drug’s approval by the FDA in 2014, Novo Nordisk has promoted Saxenda as a weight loss solution without adequately disclosing the potential for gastrointestinal disorders, despite clinical trials indicating such risks.
The exact mechanism by which Saxenda may contribute to the development of gastroparesis is not yet fully understood. However, it is thought that the medication may affect the nerves and muscles in the stomach, leading to a disruption in gastric motility. This can result in the delayed emptying of food from the stomach, causing the symptoms associated with gastroparesis. It normally takes around six to eight hours for food to pass from the stomach to the small intestine. With gastroparesis, however. the digestion process is extended with the amount of extension differing from person to person. One study which was published in the Lancet Gastroenterology and Hepatology observed how liraglutide affected digestion. The participants in the study took either liraglutide or a placebo for five weeks and then ate a meal containing a radioactive tracer which allowed researchers to see how long the food stayed in their stomachs.
These Saxenda side effects can range from mild impairment of kidney function to severe kidney damage. It is important for patients taking Saxenda to be aware of the potential risk and to closely monitor their kidney function through regular blood tests with their physician. Saxenda and Gallbladder Disease – One of the more concerning side effects of Saxenda is its potential connection to gallbladder disease. The gallbladder is a small organ located beneath the liver, responsible for storing bile, a substance that aids in the digestion of fats. Studies have shown that Saxenda can increase the risk of gallbladder-related problems, such as gallstones and inflammation. Gallstones are solid deposits that form in the gallbladder, often causing pain and discomfort. In severe cases, gallstones can lead to more serious conditions, such as cholecystitis or pancreatitis.
Moreover, healthcare professionals have reported an increase in the number of patients presenting with severe gastrointestinal issues, such as persistent vomiting, after starting Saxenda or similar GLP-1 agonist medications. These reports have raised significant concerns about the potential for Saxenda to contribute to the development of gastroparesis and other debilitating Saxenda side effects. Intestinal blockages have been reported by certain individuals who have taken Saxenda (liraglutide). These blockages can hinder the movement of food and waste through the intestines, leading to intense discomfort, swelling, and vomiting. It appears that this one of the Saxenda side effects is more prevalent in males and in those who have been using the medication for a shorter duration. In 2017, eight cases were documented, with the majority of them requiring surgical intervention. Nevertheless, the specific process by which Saxenda induces these blockages is still not fully understood.
Saxenda has been linked to an increased risk of kidney failure, which can have severe consequences if left untreated. Additionally, individuals taking Saxenda may experience episodes of low blood sugar, which can be particularly dangerous for those with pre-existing conditions like diabetes.
If you took Saxenda and developed gallbladder disease, Saxenda stomach paralysis, or any other serious Saxenda side effects, contact Timothy L. Miles, a Sazenda lawyer in Nashville, today. ?You may be eligible for a Saxenda Lawsuit ?and possibly may be entitled to substantial compensation. Discover extra information on https://www.masstortsheadquarters.com/saxenda-lawsuit.html/.
?Timothy L. Miles is a plaintiff’s lawyer in Nashville, Tennessee, and a nationally known top-rated class action and product liability lawyer who has been leading the fight to protect the rights of injured victims for over 20 years.
Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for injured victims, consumers, and shareholders, shaped precedent-setting decisions, and delivered real reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards.